melanoma
Melanoma: new treatments and hopes
September 19, 2011Research and Development advanced melanoma, melanoma, skin cancer
It usually starts with a subtle change of colour or shape in an existing mole. But if left undiagnosed and …
Roche skin cancer drug approval ‘imminent’
August 11, 2011Sales and Marketing Roche, melanoma, vemurafenib
Skin cancer treatment Zelboraf looks set to gain FDA approval months ahead of schedule. Roche and Daiichi Sankyo’s drug is …
BMS and Roche to team up in melanoma
June 3, 2011Sales and Marketing BMS, Roche, melanoma, oncology
Bristol-Myers Squibb and Roche are to use two of their drugs in an exploratory phase I/II study a bid to …
New melanoma drug approved by FDA
March 28, 2011Sales and Marketing BMS, melanoma
Yervoy, Bristol Myers Squibb’s new treatment for advanced skin cancer has gained approval in the US. The drug is the …
Daiichi Sankyo gains rights to potential blockbuster cancer drug
March 2, 2011Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine
Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
Melanoma: intense competition to be the next milestone treatment
February 9, 2011Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab
A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …
GSK skin cancer drugs moves into phase III
January 25, 2011Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer
GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …
Patient deaths halt Lilly cancer trial
December 15, 2010Research and Development Eli Lilly, lilly, melanoma, skin cancer, tasisulam
Lilly has been forced to halt phase III trials of its melanoma candidate tasisulam due to serious safety concerns over …
Pfizer signs ‘personalised’ cancer collaboration
January 15, 2010Research and Development Cancer, Debiopharm, Pfizer, melanoma, skin cancer, tremelimumab
Pfizer is to co-develop its monoclonal antibody treatment for advanced melanoma with Swiss company Debiopharm. The companies will conduct phase …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
